Funding & VC

VitusCare raises $3 Mn Series B to push past 100 dialysis centres

VitusCare has raised $3 million in Series B funding from Liberty Ridge Capital, HDFC Bank and others, after nearly tripling revenue and expanding to 60-plus dialysis centres across nine states.

By Olivia Hart

3 min read

Dialysis care provider VitusCare raises $3 Mn in Series B round
Dialysis care provider VitusCare raises $3 Mn in Series B roundMufid Majnun / unsplash

What's News

  • VitusCare raised $3 million in a Series B round with Liberty Ridge Capital, HDFC Bank and existing investors 1Crowd and 3i Partners.
  • The company has grown from 22 to over 60 dialysis centres across nine states and 50-plus cities since 2024.
  • VitusCare reported positive corporate EBITDA in FY26 with same-centre growth above 30%.
  • It targets more than 100 centres by end of FY27 and is exploring select Asian markets.
  • Competitor DCDC Kidney Care raised Rs 150 crore from ABC Impact in March 2025.

Dialysis care provider VitusCare has raised $3 million in a Series B round, with Singapore-based healthcare growth equity firm Liberty Ridge Capital joining HDFC Bank, Equentis, NAFA Capital Advisors, existing investors 1Crowd and 3i Partners, and several angel investors.

The Gurugram-based company disclosed the round in a press release. It had previously raised $2.7 million in a Series A led by Tomorrow Capital in April 2024, and Rs 10.83 crore in a seed round in 2019. In plain terms, the new round lifts VitusCare's known funding to roughly $8 million-equivalent across three rounds since inception.

What will the money fund?

The fresh capital will go toward expanding the dialysis centre network, technology development, workforce training and international expansion, the company said. Specific allocation figures were not disclosed — a gap worth noting given how quickly the prior round's capital was converted into footprint.

VitusCare has nearly tripled its revenue since its 2024 round, according to the company. Its network has grown from 22 to more than 60 dialysis centres across nine states and over 50 cities. The workforce has expanded from 110 to 300 employees.

The growth is real in volume terms: more than 35,000 patients treated and over 8 lakh (800,000) dialysis sessions conducted to date. That averages out to roughly 23 sessions delivered per centre per working day across the current network — a throughput figure the company did not itself break out.

Is the business profitable?

VitusCare said it reported positive corporate EBITDA in FY26, supported by faster breakeven at newly opened centres and same-centre growth of over 30%. EBITDA is not net profit, and the company did not disclose absolute revenue or margin figures. The claim, while a milestone, remains self-reported and unaudited in the press release.

Founded in 2017 by Prabhat Shrivastava, VitusCare operates a capital-light 'shop-in-shop' model. It partners with existing hospitals to provide specialised dialysis services rather than building standalone facilities.

Under this structure, dialysis providers supply equipment, trained medical professionals, technology and operational support while using the hospitals' existing infrastructure. The approach cuts capital expenditure and is particularly suited to Tier II and III cities, where standalone facility economics are harder to justify.

Who is VitusCare up against?

The company competes with NephroPlus, Apex Kidney Care, DCDC Kidney Care, 7Med and Rahi Care. Investor appetite in the segment has not cooled: DCDC Kidney Care raised Rs 150 crore from Temasek-backed ABC Impact in March 2025, and The Renal Project secured $1.3 million in a pre-seed round led by JITO Angel Network in September 2026.

That pace of funding suggests capital sees durable demand in Indian dialysis care. It also means VitusCare's $3 million round is modest against rivals raising multiples of that amount.

What comes next?

VitusCare aims to expand its network to more than 100 centres by the end of FY27 — a near-doubling from the current 60-plus. It is also exploring opportunities in select Asian markets, though no target countries or timelines were named.

On the technology side, the company is developing AI-native business modules to improve healthcare delivery. It also plans to establish a Technician Academy to train dialysis professionals, a pipeline it will need if the 100-centre target is to be staffed.

The takeaway: VitusCare has proven it can scale centres and reach corporate EBITDA, but hitting 100 centres and entering foreign markets on $3 million will test how capital-light the shop-in-shop model really is.

Source: entrackr.com

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,404 articles

Related articles

« Previous articleNext article »